Wiersma Jacobijne J, Meuwese Marijn C, van Miert Joram N I, Kastelein Arnoud, Tijssen Jan G P, Piek Jan J, Trip Mieke D
Department of Cardiology, Academic Medical Center, Amsterdam, The Netherlands.
Med Sci Monit. 2008 Aug;14(8):CR406-10.
Diabetes mellitus type 2 is linked to augmented endothelial dysfunction and accelerated atherosclerosis. Myeloperoxidase plays an important role in the initiation, progression, and the complications of atherosclerosis. We investigated whether myeloperoxidase levels are increased in diabetic patients.
MATERIAL/METHODS: We compared baseline plasma myeloperoxidase levels in diabetic and nondiabetic patients with mild, stable anginal complaints (Canadian Cardiovascular Society I-II/IV) and performed multivariate linear regression analyses to adjust for possible confounding factors.
A total of 440 patients were recruited from the outpatient clinic of cardiology, 268 patients with and 172 without diabetes mellitus type 2. Levels of myeloperoxidase were significantly higher in diabetic patients (median, 141 pM; interquartile range, 115-171 pM) than in nondiabetic patients (median, 126 pM; interquartile range, 105-167 pM) (P=0.01). Diabetes mellitus type 2, age in years, current smoking status, presence of hypercholesterolemia, and use of calcium antagonists and ACE inhibitors were associated with logarithmically transformed myeloperoxidase levels. Of these variables, diabetes mellitus type 2 (beta 0.096, SE 0.038, P=0.01); age (beta 0.01, SE 0.002, P<0.001), and current smoking (beta 0.166, SE 0.05, P=0.001) remained independently associated with myeloperoxidase levels in multivariate analysis. The linear regression coefficient of diabetes mellitus type 2 in relation to myeloperoxidase was 0.092 in univariate linear regression and 0.078 after adjusting for age, current smoking, and use of ACE inhibitors and calcium antagonists.
Diabetes mellitus type 2 is associated with mildly increased levels of myeloperoxidase, independent of other clinical variables. This association may contribute to the accelerated progression of atherosclerosis in diabetics.
2型糖尿病与内皮功能障碍加剧和动脉粥样硬化加速有关。髓过氧化物酶在动脉粥样硬化的发生、发展及并发症中起重要作用。我们研究了糖尿病患者的髓过氧化物酶水平是否升高。
材料/方法：我们比较了患有轻度、稳定型心绞痛（加拿大心血管学会I-II/IV级）的糖尿病患者和非糖尿病患者的基线血浆髓过氧化物酶水平，并进行多变量线性回归分析以调整可能的混杂因素。
共从心脏病门诊招募了440名患者，其中268名患有2型糖尿病，172名未患2型糖尿病。糖尿病患者的髓过氧化物酶水平（中位数为141 pM；四分位间距为115 - 171 pM）显著高于非糖尿病患者（中位数为126 pM；四分位间距为105 - 167 pM）（P = 0.01）。2型糖尿病、年龄（岁）、当前吸烟状况、高胆固醇血症的存在以及钙拮抗剂和ACE抑制剂的使用与对数转换后的髓过氧化物酶水平相关。在这些变量中，2型糖尿病（β 0.096，标准误0.038，P = 0.01）、年龄（β 0.01，标准误0.002，P < 0.001）和当前吸烟（β 0.166，标准误0.05，P = 0.001）在多变量分析中仍与髓过氧化物酶水平独立相关。在单变量线性回归中，2型糖尿病与髓过氧化物酶的线性回归系数为0.092，在调整年龄、当前吸烟以及ACE抑制剂和钙拮抗剂的使用后为0.078。
2型糖尿病与髓过氧化物酶水平轻度升高相关，独立于其他临床变量。这种关联可能导致糖尿病患者动脉粥样硬化加速进展。
